RemeGen Highlights Research at ASCO 2024, Showcases Global Cancer Treatment Innovations

YANTAI, China, June 5, 2024 – RemeGen Co., Ltd., a prominent biotechnology firm, showcased its innovative strides in global cancer treatment at the American Society of Clinical Oncology Annual Meeting (ASCO 2024) in Chicago, from May 31 to June 4, 2024. The company highlighted significant research findings, particularly involving its proprietary antibody drug conjugates (ADCs), Disitamab Vedotin (RC48) and RC88. RemeGen's contributions to the event included one Clinical Science Symposium, five Poster presentations, and ten online Abstracts, addressing various cancer types such as gastric, bladder, and gynecological tumors through both monotherapy and combination therapies.

Dr. Jianmin Fang, CEO of RemeGen, expressed pride in presenting their latest research at such a prestigious event, reinforcing RemeGen's leadership in the field of antibody-drug conjugates in China and their ongoing commitment to advancing cancer treatment options globally.

Clinical Science Symposium

At the Clinical Science Symposium, Professor Song Li of Qilu Hospital, Shandong University, presented an oral report on a Phase II trial. The study examined the efficacy of disitamab vedotin (RC48) combined with toripalimab and the oral drug S-1 in treating HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma. This randomized, controlled, multicenter, single-arm trial showcased promising results.

Poster Sessions

During the poster sessions, Professor Sheng Xinan from Peking University Cancer Hospital shared findings from a Phase II study (Poster #263) on the neoadjuvant treatment with disitamab vedotin plus toripalimab in patients with HER2-expressing muscle-invasive bladder cancer (MIBC). The research focused on the preliminary efficacy and safety of RC48-C017. The current standard treatment for MIBC is neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy and pelvic lymph node dissection. Disitamab vedotin, whether used alone or with toripalimab, showed significant anti-tumor activity in metastatic urothelial carcinoma. The Phase II trial revealed that disitamab vedotin plus toripalimab was both effective and safe as a perioperative therapy for MIBC patients, warranting further investigation.

Additional poster presentations included:
- A Phase II multi-center study (Poster #311a) on adjuvant or rescue therapy with disitamab vedotin (RC48-ADC) for high-risk non-muscle invasive bladder cancer with HER2 expression.
- A prospective, single-arm, single-center clinical study (Poster #513a) on disitamab vedotin combined with toripalimab in advanced penile cancer patients who progressed on or are intolerant to cisplatin chemotherapy.

Online Abstract Publications

Ten online abstracts accepted by ASCO showcased RemeGen's research on RC48 and RC88 in bladder, breast, and gastrointestinal cancers, underscoring the company's prolific innovation in global cancer treatment.

About ASCO

The ASCO 2024 meeting is a premier platform for improving quality care in oncology, featuring panels led by experts implementing innovative programs focused on value. ASCO’s network of nearly 42,350 oncology professionals is dedicated to providing top-tier resources in education, policy, clinical research, and advancing cancer patient care.

About RemeGen Co. Ltd.

Established in 2008, RemeGen (9995.HK, SHA: 688331) is a leading biopharmaceutical company in China, addressing unmet clinical needs for patients with life-threatening diseases. With research facilities and offices in China and the United States, RemeGen focuses on discovering, developing, and commercializing innovative biologic drugs in key therapeutic areas, including autoimmune, oncology, and ophthalmic diseases.

About Disitamab Vedotin (RC48)

Disitamab Vedotin (RC48) is an investigational anti-HER2 antibody-drug conjugate targeting prevalent solid cancers with significant unmet needs. It is the first domestically developed ADC approved for marketing in China. RemeGen employs a differentiated strategy for disitamab vedotin, focusing on gastric cancer, urothelial carcinoma, breast cancer, and other HER2-expressing cancers.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!